Search

Your search keyword '"Van Krieken, J. Han"' showing total 388 results

Search Constraints

Start Over You searched for: Author "Van Krieken, J. Han" Remove constraint Author: "Van Krieken, J. Han" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
388 results on '"Van Krieken, J. Han"'

Search Results

2. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma

3. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

4. Detection of Second Primary Lymphoma in Late Diffuse Large B-cell Lymphoma Recurrences

6. Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer.

12. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

14. Self-Supervised Learning Reveals Clinically Relevant Histomorphological Patterns for Therapeutic Strategies in Colon Cancer

16. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

17. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma

19. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program

20. e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study

22. Gastric Antrum (Distal Stomach)

23. Ménétrier’s Disease

24. Autoimmune Gastritis

25. Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma

27. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma

28. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

29. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

30. Gastric Cardia (Proximal Stomach)

34. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

35. Consensus molecular subtype transition during progression of colorectal cancer

36. Supplementary Tables from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

37. Data from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

38. Data from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

39. Supplementary Tables 1-5 and Supplementary Figures 1-8 from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

40. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

41. Supplementary Figures 1-3 from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

42. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

44. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

45. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1

46. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions

48. Supplmentary Documents including Methods, Tables, and Legends for Supplementary Figures, and Supplementary Figure S1-S5 from Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

49. Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

50. Supplementary Table 1 from T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

Catalog

Books, media, physical & digital resources